Literature DB >> 20189487

Promiscuous T-cell epitopes of Plasmodium merozoite surface protein 9 (PvMSP9) induces IFN-gamma and IL-4 responses in individuals naturally exposed to malaria in the Brazilian Amazon.

J C Lima-Junior1, D M Banic, T M Tran, V S E Meyer, S G De-Simone, F Santos, L C S Porto, M T Q Marques, A Moreno, J W Barnwell, M R Galinski, J Oliveira-Ferreira.   

Abstract

Plasmodium vivax merozoite surface protein (PvMSP9) stimulates both cellular and humoral immune responses in individuals who are naturally infected by this parasite species. To identify immunodominant human T-cell epitopes in PvMSP9, we used the MHC class II binding peptide prediction algorithm ProPred. Eleven synthetic peptides representing predicted putative promiscuous T-cell epitopes were tested in IFN-gamma and IL-4 ELISPOT assays using peripheral blood mononuclear cells (PBMC) derived from 142 individuals from Rondonia State, Brazil who had been naturally exposed to P. vivax infections. To determine whether the predicted epitopes are preferentially recognized in the context of multiple alleles, MHC Class II typing of the cohort was also performed. Five synthetic peptides elicited robust cellular responses, and the overall frequencies of IFN-gamma and IL-4 responders to at least one of the promiscuous peptides were 62% and 46%, respectively. The frequencies of IFN-gamma and IL-4 responders to each peptide were not associated with a particular HLA-DRB1 allelic group since most of the peptides induced a response in individuals of 12 out of 13 studied allelic groups. The prediction of promiscuous epitopes using ProPred led to the identification of immunodominant epitopes recognized by PBMC from a significant proportion of a genetically heterogeneous population exposed to malaria infections. The combination of several such T-cell epitopes in a vaccine construct may increase the frequency of responders and the overall efficacy of subunit vaccines in genetically distinct populations. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20189487      PMCID: PMC2861348          DOI: 10.1016/j.vaccine.2010.02.046

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  48 in total

1.  Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes.

Authors:  E H Nardin; G A Oliveira; J M Calvo-Calle; Z R Castro; R S Nussenzweig; B Schmeckpeper; B F Hall; C Diggs; S Bodison; R Edelman
Journal:  J Infect Dis       Date:  2000-10-09       Impact factor: 5.226

2.  Family-based association of HLA class II alleles and haplotypes with type I diabetes in Brazilians reveals some characteristics of a highly diversified population.

Authors:  W M Volpini; G V Testa; S B Marques; L I Alves; M E Silva; S A Dib; G Guerra; M F Paulino; S H Marini; L B Persoli; S Caillat-Zucman
Journal:  Hum Immunol       Date:  2001-11       Impact factor: 2.850

3.  ProPred: prediction of HLA-DR binding sites.

Authors:  H Singh; G P Raghava
Journal:  Bioinformatics       Date:  2001-12       Impact factor: 6.937

Review 4.  Malaria vaccines: from the laboratory to the field.

Authors:  Blaise Genton; Giampietro Corradin
Journal:  Curr Drug Targets Immune Endocr Metabol Disord       Date:  2002-10

5.  HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles.

Authors:  D L Doolan; S Southwood; R Chesnut; E Appella; E Gomez; A Richards; Y I Higashimoto; A Maewal; J Sidney; R A Gramzinski; C Mason; D Koech; S L Hoffman; A Sette
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

6.  Assessing the binding of four Plasmodium falciparum T helper cell epitopes to HLA-DQ and induction of T-cell responses in HLA-DQ transgenic mice.

Authors:  N Pimtanothai; M Parra; A H Johnson; C S David; C Katovich Hurley
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

7.  A strategy for the identification of T-cell epitopes on Leishmania cysteine proteinases.

Authors:  C R Alves; L C Pontes de Carvalho; A L Souza; S G De Simone
Journal:  Cytobios       Date:  2001

8.  Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope of Plasmodium falciparum merozoite surface protein 1 displaying dimorphic amino acid polymorphism are highly constrained.

Authors:  Claudia A Daubenberger; Beatrice Nickel; Carlo Ciatto; Markus G Grütter; Friederike Pöltl-Frank; Laura Rossi; Uwe Siegler; John Robinson; Oscar Kashala; Manuel Elkin Patarroyo; Gerd Pluschke
Journal:  Eur J Immunol       Date:  2002-12       Impact factor: 5.532

9.  Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans.

Authors:  Jia Xainli; Moses Baisor; Will Kastens; Moses Bockarie; John H Adams; Christopher L King
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

10.  Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens.

Authors:  Ivette Caro-Aguilar; Alexandra Rodríguez; J Mauricio Calvo-Calle; Fanny Guzmán; Patricia De la Vega; Manuel Elkin Patarroyo; Mary R Galinski; Alberto Moreno
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

View more
  14 in total

1.  Improved proteomic approach for the discovery of potential vaccine targets in Trypanosoma cruzi.

Authors:  Ernesto S Nakayasu; Tiago J P Sobreira; Rafael Torres; Luciane Ganiko; Paulo S L Oliveira; Alexandre F Marques; Igor C Almeida
Journal:  J Proteome Res       Date:  2011-12-08       Impact factor: 4.466

2.  B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian Amazon.

Authors:  J C Lima-Junior; J Jiang; R N Rodrigues-da-Silva; D M Banic; T M Tran; R Y Ribeiro; V S E Meyer; S G De-Simone; F Santos; A Moreno; J W Barnwell; M R Galinski; J Oliveira-Ferreira
Journal:  Vaccine       Date:  2011-01-06       Impact factor: 3.641

3.  The evolution and diversity of a low complexity vaccine candidate, merozoite surface protein 9 (MSP-9), in Plasmodium vivax and closely related species.

Authors:  Stella M Chenet; M Andreína Pacheco; David J Bacon; William E Collins; John W Barnwell; Ananias A Escalante
Journal:  Infect Genet Evol       Date:  2013-09-14       Impact factor: 3.342

4.  MultiRTA: a simple yet reliable method for predicting peptide binding affinities for multiple class II MHC allotypes.

Authors:  Andrew J Bordner; Hans D Mittelmann
Journal:  BMC Bioinformatics       Date:  2010-09-24       Impact factor: 3.169

5.  Bioinformatic and empirical analysis of novel hypoxia-inducible targets of the human antituberculosis T cell response.

Authors:  Hannah P Gideon; Katalin A Wilkinson; Tige R Rustad; Tolu Oni; Heinner Guio; David R Sherman; H Martin Vordermeier; Brian D Robertson; Douglas B Young; Robert J Wilkinson
Journal:  J Immunol       Date:  2012-11-19       Impact factor: 5.422

6.  Influence of HLA-DRB1 and HLA-DQB1 alleles on IgG antibody response to the P. vivax MSP-1, MSP-3α and MSP-9 in individuals from Brazilian endemic area.

Authors:  Josué C Lima-Junior; Rodrigo N Rodrigues-da-Silva; Dalma M Banic; Jianlin Jiang; Balwan Singh; Gustavo M Fabrício-Silva; Luís C S Porto; Esmeralda V S Meyer; Alberto Moreno; Maurício M Rodrigues; John W Barnwell; Mary R Galinski; Joseli de Oliveira-Ferreira
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

7.  Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins.

Authors:  Maria Agallou; Evita Athanasiou; Olga Koutsoni; Eleni Dotsika; Evdokia Karagouni
Journal:  Front Immunol       Date:  2014-06-10       Impact factor: 7.561

Review 8.  Major Histocompatibility Complex and Malaria: Focus on Plasmodium vivax Infection.

Authors:  Josué da Costa Lima-Junior; Lilian Rose Pratt-Riccio
Journal:  Front Immunol       Date:  2016-01-27       Impact factor: 7.561

9.  In silico Identification and Validation of a Linear and Naturally Immunogenic B-Cell Epitope of the Plasmodium vivax Malaria Vaccine Candidate Merozoite Surface Protein-9.

Authors:  Rodrigo Nunes Rodrigues-da-Silva; João Hermínio Martins da Silva; Balwan Singh; Jianlin Jiang; Esmeralda V S Meyer; Fátima Santos; Dalma Maria Banic; Alberto Moreno; Mary R Galinski; Joseli Oliveira-Ferreira; Josué da Costa Lima-Junior
Journal:  PLoS One       Date:  2016-01-20       Impact factor: 3.240

10.  Naturally acquired immune responses to P. vivax merozoite surface protein 3α and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children.

Authors:  Danielle I Stanisic; Sarah Javati; Benson Kiniboro; Enmoore Lin; Jianlin Jiang; Balwan Singh; Esmeralda V S Meyer; Peter Siba; Cristian Koepfli; Ingrid Felger; Mary R Galinski; Ivo Mueller
Journal:  PLoS Negl Trop Dis       Date:  2013-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.